The pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has upended healthcare systems and economies around the world. Rapid understanding of the structural biology and pathogenesis of SARS-CoV-2 has allowed the development of emergency use or FDA-approved vaccines and various candidate vaccines. Among the recently developed SARS-CoV-2 candidate vaccines, natural protein-based nanoparticles well suited for multivalent antigen presentation and enhanced immune stimulation to elicit potent humoral and cellular immune responses are currently being investigated. This mini-review presents recent innovations in protein-based nanoparticle vaccines against SARS-CoV-2. The design and strategy of displaying antigenic domains, including spike protein, receptor-binding domain (RBD), and other domains on the surface of various protein-based nanoparticles and the performance of the developed nanoparticle-based vaccines are highlighted. In the final part of this review, we summarize and discuss recent advances in clinical trials and provide an outlook on protein-based nanoparticle vaccines.
【저자키워드】 SARS-CoV-2, Vaccines, nanomedicine, nanovaccine, protein nanoparticles, protein-based nanotechnology, 【초록키워드】 Vaccine, clinical trial, pandemic, Cellular immune response, Spike protein, RBD, Rapid, Antigen presentation, Emergency use, Coronavirus-2, Healthcare system, humoral, acute respiratory syndrome, domains, antigenic, domain, Final, immune stimulation, pathogenesis of SARS-CoV-2, caused, investigated, elicit, displaying, 【제목키워드】 nanoparticle,